In the past decade, the number of oncology trials has experienced an astonishing surge, nearly doubling the combined count of trials in all other therapeutic areas, as reported by the WIRB-Copernicus Group¹. Oncology trials, renowned for their intricate designs, frequently pose numerous challenges to participants, research sites, and sponsors, jeopardizing their successful execution. To enhance the design of oncology studies, organizations must confront the issues encountered by participants and research sites.
Sponsors and Contract Research Organizations (CROs) seeking to address these issues and alleviate the burdens on participants and sites should consider the potential of digital solutions, especially electronic informed consent (eConsent) and electronic patient-reported outcomes (ePRO). These tools not only provide comprehensive insights into the participant journey but also furnish valuable feedback, empowering sponsors and CROs to improve and optimize their trials for the benefit of all stakeholders.
Through the adoption of digital solutions, the integration of ePRO measures, the standardization of assessments, and a focus on flexibility and choice, sponsors and CROs can alleviate the challenges faced by participants and research sites. Find out how you can make life easier for patients when it matters most by accessing the white paper below.